Deletion of serine/threonine-protein kinase pknL from Mycobacterium tuberculosis reduces the efficacy of isoniazid and ethambutol. (May 2021)

• Record Type: Journal Article
• Authors: Naz, Saba; Singh, Yogendra; Nandicoori, Vinay Kumar
• Is Part Of: Tuberculosis. Volume 128(2021)
• Publication Date: 2021-05
• Subjects: Tuberculosis -- Mycobacteria -- STPK -- Kinase -- Antibiotic; 616.995
• DOI: 10.1016/j.tube.2021.102066
• Languages: English
• ISSNs: 1472-9792

Abstract

Abstract: Serine/threonine-protein kinases in Mycobacterium tuberculosis ( Mtb ) form a preeminent regulatory system required to establish and maintain the infection in the host. Herein, we sought to decipher the biological role of PknL with the help of a gene replacement mutant RvΔpknL . Deletion of pknL results in the compromised growth under redox stress. The mutant showed significant survival defects in peritoneal macrophages, a significant decrease in the ability to establish infections and disseminate to the spleen in the murine model of infection. While the absence of pknL has no impact on either MIC or CFUs of ciprofloxacin and rifampicin treated bacilli, it increases the survival ~1.5–2.5 log fold upon isoniazid or ethambutol treatment. Collectively, data suggests that PknL aids in combating stress conditions in vitro, ex vivo, and in vivo and reduces the efficacy of isoniazid and ethambutol.